Key Takeaways
- Foreign investors offloaded a record 7.7 trillion won ($4.98 billion) in KOSPI stocks on Monday, the largest single-day net sale in South Korean history, amid fears of an overheating AI sector.
- China blacklisted 40 Japanese entities, including divisions of Mitsubishi Corporation (MSBHF), imposing strict export controls on "dual-use" items to curb Japan's military modernization.
- AstraZeneca (AZN) triggered a $25 million milestone payment to Daiichi Sankyo (DSNKY) following EU approval of Enhertu as the first tumor-agnostic HER2-directed therapy.
- Bridgepoint (BPT) committed $1.4 billion to acquire a U.S. real estate unit, signaling a major contrarian bet on the recovery of the American property market.
- Iran and Oman convened the first "Hormuz Joint Committee" in Muscat to discuss the future management of the strategic Strait of Hormuz following a recent memorandum with Washington.
South Korean Markets Hit "Danger Zone" as AI Rally Fractures
The South Korean stock market faced a historic rout on Monday as foreign investors withdrew 7.7 trillion won from the KOSPI. This massive exit follows a period of extreme concentration where Samsung Electronics (SMSN) and SK Hynix (000660) grew to represent 60% of the total index value.
Analysts at the Wall Street Journal warned that the market has entered a "danger zone" due to this heavy reliance on the AI-driven semiconductor trade. Regulators have already intervened twice to pause trading as volatility spikes, with Samsung shares falling over 5% in early Monday trading.
Beijing Escalates Economic Pressure on Tokyo
China’s Ministry of Commerce announced new trade restrictions against 40 Japanese companies and research institutes on Monday. The move targets entities Beijing claims are contributing to Japan's "remilitarization," including the National Institute for Defense Studies and multiple divisions of Mitsubishi Corporation (MSBHF).
These export controls prohibit the sale of dual-use items—goods that can be utilized for both civilian and military purposes—originating from China. The escalation follows months of diplomatic friction and significantly complicates supply chains for Japanese defense and technology contractors.
Pharmaceutical and Private Equity Giants Make Strategic Moves
In the healthcare sector, AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) reached a major regulatory milestone. The European Union approved their drug Enhertu for all HER2-positive metastatic solid tumors, regardless of where the cancer originated. This "tumor-agnostic" approval is a first for the EU and necessitates a $25 million payment from AstraZeneca to its Japanese partner.
Simultaneously, UK-based private equity firm Bridgepoint (BPT) is doubling down on the U.S. economy with a $1.4 billion acquisition of a real estate investment unit. The move suggests institutional confidence that U.S. property valuations may be bottoming out after a period of high interest rates.
Geopolitical Shifts in the Strait of Hormuz
Diplomatic efforts intensified in the Middle East as Iranian Deputy Foreign Minister Kazem Gharibabadi met with Omani officials in Muscat. The inaugural meeting of the Hormuz Joint Committee focused on the future management of the world’s most important oil chokepoint.
The discussions are reportedly based on a Memorandum of Understanding signed earlier this month between Tehran and Washington. Both nations reaffirmed their commitment to the "safe passage" of international shipping while asserting the sovereign rights of coastal states over the waterway.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.